港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

813.086

-16.455-1.98%

涨家数：15

跌家数：18

平家数：1

市盈率：- -

高：838.098

开：829.730

低：798.982

收：829.540

成交量：2.99亿

成交额：68.76亿

市值：4,867.91亿

流通市值：4,431.37亿

数据加载中...

国产创新药靠BD大火医疗器械能否复制这一路径？

8月26日再鼎医药在港交所公告上半年产品收入净额同比增加15%至2.15亿美元；研发开支同比减少4%至1.11亿美元；亏

中药上市公司半年报纷纷提及加大创新药研发

再鼎医药(09688)发布中期业绩，总收入2.16亿美元同比增加15.35%

医药板块下跌特朗普再放狠话：下调药品价格1400%至1500%

华丽家族股价持平 3亿元增资创新药企引关注

一心堂股价持平医药商业板块成交额达2.66亿元

信立泰股价微涨0.66% 化学制药企业研发管线引关注

歌礼制药-B(01672)8月25日发行2882万股

新股消息 | 劲方医药通过港交所聆讯报告期内持续亏损

先瑞达医疗-B(06669)：外周可控机械解脱带纤维毛弹簧圈的注册申请获中国国家药品监督管理局批准

先瑞达医疗-B获得中国国家药监局批准其外周可控机械分离纤维弹簧圈产品

据港交所文件：劲方医药科技股份有限公司 - B通过港交所上市聆讯。

据港交所文件：劲方医药科技（上海）股份有限公司 - B通过港交所上市聆讯。

富国基金赵伟：创新药行情才刚刚开始下一个10倍股可能来自自免和代谢领域

归创通桥(02190)8月25日斥资118.42万港元回购5万股

腾盛博药-B(02137)因受限制股份单位获归属而发行13.08万股

集采倒逼传统药企转型，多家企业创新药收入贡献过半

恒瑞医药(01276.HK)：HRS-2162注射液获药物临床试验批准通知书

研报掘金丨平安证券：维持鱼跃医疗“强烈推荐”评级，看好公司持续增长能力

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1574/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":813.08563,"timestamp":1756109316218,"preClose":829.54016,"halted":0,"volume":299050551,"delay":0,"changeRate":-0.019836,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-16.454529,"latestTime":"08-25 16:00:00","open":829.7301,"high":838.09845,"low":798.9819,"amount":6876007852,"amplitude":0.047155,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1756171800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1756085400000,1756094400000],[1756098000000,1756108800000]],"pbRate":6.722096,"peRate":-40.784235,"turnoverRate":0.011142,"increases":14,"decrements":18,"flats":1,"marketCap":486790530176,"floatMarketCap":443137092448},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":838.09845,"amplitude":0.047155,"preClose":829.54016,"low":798.9819,"pbRate":"6.722096","latestPrice":813.08563,"volume":299050551,"delay":0,"open":829.7301,"prevYearClose":331.1933,"prevWeekClose":829.54,"prevMonthClose":735.033,"prevQuarterClose":555.617,"fiveDayClose":840.007,"twentyDayClose":745.968,"sixtyDayClose":491.683,"secType":"PLATE","market":"HK","turnoverRate":0.011142,"peRate":-40.784235,"marketCap":486790530176,"floatMarketCap":443137092448,"timestamp":1756109316218,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":15,"down":18,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562027949","title":"国产创新药靠BD大火 医疗器械能否复制这一路径？","url":"https://stock-news.laohu8.com/highlight/detail?id=2562027949","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562027949?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 07:52","pubTimestamp":1756165922,"startTime":"0","endTime":"0","summary":"【国产创新药靠BD大火 医疗器械能否复制这一路径？】“BD（业务发展）是个大热点，我们最近的一次线上会起码有一半时间，分析师都在问相关话题。”近期，一位国内医疗器械行业人士向澎湃新闻记者发出了这样的感慨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202508263494220491.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508263494220491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1100","BK1222","BK1574","BK1161","09997","09996","BK1583"],"gpt_icon":0},{"id":"2562276974","title":"8月26日再鼎医药在港交所公告上半年产品收入净额同比增加15%至2.15亿美元；研发开支同比减少4%至1.11亿美元；亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2562276974","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562276974?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 07:09","pubTimestamp":1756163380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09688","BK1574","BK4139","BK1588","HEXmain","BK4526","BK4585","BK4531","BK4588","BK1161","BK4548","ZLAB","LU2488822045.USD"],"gpt_icon":0},{"id":"2562764812","title":"中药上市公司半年报纷纷提及加大创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2562764812","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562764812?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 07:09","pubTimestamp":1756163340,"startTime":"0","endTime":"0","summary":"　　同花顺数据显示，截至8月25日，共计27家中药上市公司发布2025年半年度业绩报告。其中，10家上半年营业收入实现正增长，增幅超10%的有6家；13家归属于上市公司股东的净利润实现正增长，占比约48%。　　当前，我国医药行业正处于从传统医药向创新医药转型的关键发展阶段。　　从已披露的半年报看，上半年中药上市公司经营“喜忧参半”，业绩分化明显。　　加大创新药研发也是中药上市公司在半年报中频频提及的重要战略。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2025-08-26/doc-infnhekr6991554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","159992","06978"],"gpt_icon":0},{"id":"2562276863","title":"再鼎医药(09688)发布中期业绩，总收入2.16亿美元 同比增加15.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562276863","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562276863?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 06:45","pubTimestamp":1756161948,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布2025年中期业绩，该集团取得总收入2.16亿美元，同比增加15.35%;亏损净额8916.5万美元，同比减少33.33%;每股亏损0.08美元。产品收入净额增加2750万美元(或15%)至2.15亿美元，主要由于卫伟迦的销售额受疗程延长及市场渗透率提升的推动而增长、纽再乐的销售额受市场覆盖范围及渗透率提升的推动而增长及自2024年第四季度起上市的鼎优乐的销售额增长。研发开支减少490万美元(或4%)至1.11亿美元，主要由于持续的资源优化及效率提升令人员和临床试验成本减少，部分被许可费增加所抵销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药(09688)发布中期业绩，总收入2.16亿美元 同比增加15.35%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4531","BK4548","BK4585","LU2488822045.USD","BK1588","09688","BK4139","BK1574","BK4526","BK4588","ZLAB"],"gpt_icon":0},{"id":"2562275654","title":"医药板块下跌 特朗普再放狠话：下调药品价格1400%至1500%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562275654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562275654?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 06:00","pubTimestamp":1756159200,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","159938","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"2562221405","title":"华丽家族股价持平 3亿元增资创新药企引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2562221405","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562221405?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 01:49","pubTimestamp":1756144177,"startTime":"0","endTime":"0","summary":"截至8月25日收盘，华丽家族股价报3.15元，与前一交易日持平。当日成交额达4.84亿元，换手率为9.61%。华丽家族主营业务为房地产开发，同时涉及石墨烯等新材料领域。近期公司公告拟以不超过3亿元现金认购海和药物5%-8.09%股份，跨界布局创新药领域。8月10日公司公告显示，此次投资标的海和药物已有3款创新药上市，包括治疗非小细胞肺癌的谷美替尼片等产品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26014952680099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK0077","600503","159992","BK0188","BK0273","BK0061","BK0028","BK0012","06978","BK1574","BK0131"],"gpt_icon":0},{"id":"2562229205","title":"一心堂股价持平 医药商业板块成交额达2.66亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562229205","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562229205?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 01:19","pubTimestamp":1756142343,"startTime":"0","endTime":"0","summary":"截至2025年8月25日收盘，一心堂股价报15.16元，与前一交易日持平。当日成交量为176026手，成交金额2.66亿元，换手率为4.43%。一心堂属于医药商业板块，同时涉及云南板块、内贸流通等概念。公司主要从事医药零售连锁和医药批发业务，在云南省内具有较高的市场占有率。8月25日主力资金净流出2656.6万元，占流通市值的0.44%。近五个交易日累计净流出4280.52万元，占流通市值的0.71%。风险提示：股市有风险，投资需谨慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26011952680008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK1161","002727","09939","159938","BK0209","BK0097","LU1969619763.USD","BK0077","LU2328871848.SGD","BK1574"],"gpt_icon":0},{"id":"2562226791","title":"信立泰股价微涨0.66% 化学制药企业研发管线引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2562226791","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562226791?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 00:31","pubTimestamp":1756139514,"startTime":"0","endTime":"0","summary":"信立泰最新股价报53.09元，较前一交易日上涨0.35元。盘中最高触及54.40元，最低下探52.11元，全天成交金额达5.04亿元，换手率为0.85%。该公司主营业务为化学制药，专注于心血管、抗感染、抗肿瘤等领域的创新药物研发。作为深圳特区企业，信立泰已建立起从原料药到制剂的全产业链布局，拥有多项核心专利技术。从资金流向来看，8月25日主力资金净流出5214.05万元，近五个交易日累计净流出8836.77万元。当前公司总市值591.86亿元，市盈率为81.06倍。风险提示：股市有风险，投资需谨慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26003152679708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0196","BK0187","BK1574","BK1191","BK0239","BK0028","002294","01477","BK0188","BK0183"],"gpt_icon":0},{"id":"2562264247","title":"歌礼制药-B(01672)8月25日发行2882万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2562264247","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562264247?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 21:44","pubTimestamp":1756129453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年8月25日根据日期为2025年8月19日的配售及认购协议, 根据一般授权配发及发行2882万股新股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01672","BK1574","BK1161","01477","BK1515"],"gpt_icon":0},{"id":"2562426002","title":"新股消息 | 劲方医药通过港交所聆讯 报告期内持续亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2562426002","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562426002?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 21:14","pubTimestamp":1756127690,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所8月25日披露，劲方医药科技(上海)股份有限公司通过港交所上市聆讯，中信证券为其独家保荐人。公司已在中国启动针对携带KRAS G12D突变的晚期实体瘤患者的I/II期临床试验的II期部分。KRAS G12D是最常见的致癌基因KRAS突变，尚无获批的治疗方案可用。财务方面，于2023年度、2024年度及2025年截至4月30日止四个月，劲方医药现收入分别约为7373.4万元、1.05亿元、8214.9万元人民币；年/期内亏损分别约为5.08亿元、6.78亿元、6662.4万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","09939","HEXmain","BK1574","BK1161"],"gpt_icon":0},{"id":"2562564242","title":"先瑞达医疗-B(06669)：外周可控机械解脱带纤维毛弹簧圈的注册申请获中国国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2562564242","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562564242?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 21:12","pubTimestamp":1756127538,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先瑞达医疗-B(06669)发布公告，于2025年8月22日，集团收到中国国家药品监督管理局对外周可控机械解脱带纤维毛弹簧圈的注册批准。本产品用于外周血管的动脉瘤、动静脉畸形和动静脉瘘的填塞。本产品采用可控解脱机制，确保弹簧圈释放过程稳定、精准，提升了操作的可控性和安全性。此外，产品具有2D和3D两种结构可选择，能够广泛适配临床需求。公司将适时在中国开展营销活动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK1587","BK1574","06669"],"gpt_icon":0},{"id":"1172020994","title":"先瑞达医疗-B获得中国国家药监局批准其外周可控机械分离纤维弹簧圈产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1172020994","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172020994?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 21:01","pubTimestamp":1756126890,"startTime":"0","endTime":"0","summary":"先瑞达医疗-B宣布，公司的外周可控机械分离纤维弹簧圈产品已获得中国国家药品监督管理局的正式批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1100","BK1587","06669"],"gpt_icon":0},{"id":"2562241464","title":"据港交所文件：劲方医药科技股份有限公司 - B通过港交所上市聆讯。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562241464","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562241464?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 20:27","pubTimestamp":1756124848,"startTime":"0","endTime":"0","summary":"据港交所文件：劲方医药科技股份有限公司 - B通过港交所上市聆讯。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/25202752675572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","159938","BK1161","BK1515","09939"],"gpt_icon":0},{"id":"2562524166","title":"据港交所文件：劲方医药科技（上海）股份有限公司 - B通过港交所上市聆讯。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562524166","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562524166?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 20:22","pubTimestamp":1756124521,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1515","BK1161","159938","BK1574","HEXmain"],"gpt_icon":0},{"id":"2562524658","title":"富国基金赵伟：创新药行情才刚刚开始 下一个10倍股可能来自自免和代谢领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2562524658","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562524658?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 19:27","pubTimestamp":1756121233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，富国基金基金经理赵伟分享了对医药市场尤其对创新药的看法。赵伟指出，创新药现在是起点，刚刚开始。他认为自免和代谢领域机会很大。从今年、明年开始，国内获批新药的数量还会持续增长，未来中国创新药的获批量很可能会迎来井喷。此外，这轮创新药行情的最核心逻辑是出海。肿瘤是美国和中国最大的治疗领域。赵伟表示，未来投资要看胜率和赔率，真正的大单品可能是下一个十倍股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","159992","06978"],"gpt_icon":0},{"id":"2562434462","title":"归创通桥(02190)8月25日斥资118.42万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2562434462","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562434462?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 18:50","pubTimestamp":1756119031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)发布公告，于2025年8月25日，该公司斥资118.42万港元回购5万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02190","BK1574","BK1583","BK1100","BK1587"],"gpt_icon":0},{"id":"2562724892","title":"腾盛博药-B(02137)因受限制股份单位获归属而发行13.08万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2562724892","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562724892?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 18:23","pubTimestamp":1756117393,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B(02137)发布公告，于2025年8月25日，该公司根据于2021年6月22日采纳的公司首次公开发售后股份奖励计划，归属授出的受限制股份单位而发行及配发予公司雇员的13.08万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02137","BK1587"],"gpt_icon":0},{"id":"2562439652","title":"集采倒逼传统药企转型，多家企业创新药收入贡献过半","url":"https://stock-news.laohu8.com/highlight/detail?id=2562439652","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562439652?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 18:14","pubTimestamp":1756116894,"startTime":"0","endTime":"0","summary":"2018年药品集采政策推行后，很多依赖仿制药收入的传统药企，利润在一夜之间锐减。面对这种形势，企业们纷纷吹响向创新药企转型号角。现如今，药企的转型初见成效。近日，多家药企公布的2025年半年报显示，创新药已撑起了公司一半以上的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202508253493664948.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508253493664948.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2562175242","title":"恒瑞医药(01276.HK)：HRS-2162注射液获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2562175242","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562175242?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 17:29","pubTimestamp":1756114197,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1328615791.USD","159938","BK1191","LU2543165471.USD","LU1997245094.SGD","BK0196","LU1997245177.USD","600276","BK0183","LU0359201885.HKD","01276","LU0405327148.USD","LU0405327494.USD","BK0188","BK1574","LU1064130708.USD","LU2488822045.USD","BK0239","LU1064131003.USD","LU0359201612.USD","BK1161","LU1255011170.USD","LU2328871848.SGD","09939","LU2495084118.USD","BK0028","BK1515","LU2148510915.USD","BK0012","BK0060","LU1655091616.SGD","LU1997244956.HKD","LU1023057109.AUD","LU0359202008.SGD","LU1969619763.USD","LU2580892789.USD","LU2580892862.HKD"],"gpt_icon":0},{"id":"2562521293","title":"研报掘金丨平安证券：维持鱼跃医疗“强烈推荐”评级，看好公司持续增长能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2562521293","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562521293?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 17:17","pubTimestamp":1756113448,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","BK0114","09997","BK0185","161027","BK1574","BK1222","159883","BK1100","09996","002223","BK0146","BK0197","BK0251","BK1583","BK0070"],"gpt_icon":0}],"pageSize":20,"totalPage":23,"pageCount":1,"totalSize":444,"code":"91000000","status":"200"}]}}